SEI Investments’s ADC Therapeutics ADCT Stock Holding History

SEI Investments’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$125K	Buy	33,461 +10,472	+46%	+$41.3K	﹤0.01%	3058
2025 Q4	$81.2K	Hold	22,989	–	–	﹤0.01%	3035
2025 Q3	$92K	Hold	22,989	–	–	﹤0.01%	2728
2025 Q2	$61.6K	Hold	22,989	–	–	﹤0.01%	2736
2025 Q1	$32.4K	Hold	22,989	–	–	﹤0.01%	2711
2024 Q4	$45.7K	Buy	+22,989	New	+$60.2K	﹤0.01%	2675

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SEI Investments's ADCT Position: Q1 2026 in Review

SEI Investments increased its ADC Therapeutics (ADCT) stake by 46% in Q1 2026, buying an estimated $41.3K and bringing the position to 33,461 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #3058.

SEI Investments first reported a position in ADCT in Q4 2024 and has held it in 6 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

SEI Investments held 33,461 shares of ADC Therapeutics worth $125K as of Q1 2026.
SEI Investments bought 10,472 ADC Therapeutics shares in Q1 2026, an estimated $41.3K.
ADC Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #3058 holding.
SEI Investments first reported a position in ADC Therapeutics in Q4 2024 and has held it in 6 quarters since.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.